DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)

Information source: Monash University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Heart Failure

Intervention: Spironolactone (Drug); Placebo (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Monash University

Official(s) and/or principal investigator(s):
Henry Krum, MBBS FRACP PhD, Principal Investigator, Affiliation: Monash University / Alfred Hospital

Overall contact:
Henry Krum, MBBS FRACP PhD, Phone: +61 3 9903 0042, Email: henry.krum@med.monash.edu.au

Summary

Individuals who were apart of the investigators Screen-HF study (NCT00400257) whose BNP level are in the top quintile will be offered participation in this study. Participants will be randomised to receive either spironolactone or placebo for two years. Participants will then be monitored for indications of heart failure. It is anticipated that the medication will reduce the development of heart failure in this group.

Clinical Details

Official title: SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)

Study design: Prevention, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study

Primary outcome:

Effectiveness of Spironolactone in preventing heart failure

Cost effectiveness of Spironolactone prevention

Secondary outcome:

Development of evidence of LV dysfunction, either systolic or diastolic, on echocardiography and/or symptomatic heart failure

Change in 6 minute walk test between the two groups

Change in quality of life between the two groups

Change in left ventricular remodelling parameters

Eligibility

Minimum age: 60 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Was recruited to SCREEN-HF

2. Has provided informed consent

Exclusion Criteria:

1. Uncorrected hyperkalaemia

2. eGFR < 30 ml/min

Locations and Contacts

Henry Krum, MBBS FRACP PhD, Phone: +61 3 9903 0042, Email: henry.krum@med.monash.edu.au

Alfred Hospital, Melbourne, Victoria 3004, Australia; Recruiting
Henry Krum, MBBS FRACP PhD, Phone: +61 3 9903 0042, Email: henry.krum@med.monash.edu.au
Henry Krum, MBBS FRACP PhD, Principal Investigator
Chris Reid, A/Professor, Sub-Investigator
Pupalan Iyngkaran, Doctor, Sub-Investigator
Michele McGrady, Doctor, Sub-Investigator
Additional Information

Starting date: September 2008
Ending date: April 2010
Last updated: August 18, 2009

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009